Recent characteristics and outcomes of Japanese stable angina pectoris after percutaneous coronary intervention: An observational cohort study using the Shinken database

International Heart Journal

Volumn 54, Issue 6, 2013, Pages 335-340

  Kaneko, Hidehiro ^a   Yajima, Junji ^a   Oikawa, Yuji ^a   Tanaka, Shingo ^a   Fukamachi, Daisuke ^a   Suzuki, Shinya ^a   Sagara, Koichi ^a   Otsuka, Takayuki ^a   Matsuno, Shunsuke ^a   Funada, Ryuichi ^a   Kano, Hiroto ^a   Uejima, Tokuhisa ^a   Koike, Akira ^a   Nagashima, Kazuyuki ^a   Kirigaya, Hajime ^a   Sawada, Hitoshi ^a   Aizawa, Tadanori ^a   Yamashita, Takeshi ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Japanese; Percutaneous coronary intervention (PCI); Prognosis; Stable angina pectoris (SAP)

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; TREATMENT OUTCOME; URBAN POPULATION;

EID: 84889061669     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.335     Document Type: Article

References (43)

1. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet 1998; 352: 507-514.
2. Yui Y, Hirayama A, Nonogi H, et al. Unstable angina and non-ST elevation acute coronary syndrome: epidemiology and current management in Japan (Japan Multicenter Investigation for Cardiovascular Disease-D (JMIC-D) Committee). Circ J 2007; 71: 1335-1347.
3. Nishigaki K, Yamazaki T, Fukunishi M, Tanihata S, Fujiwara H. Assessment of acute myocardial infarction in Japan by the Japanese Coronary Intervention Study (JCIS) Group. Circ J 2004; 68: 515-519.
4. Roe MT, Chen AY, Mehta RH, et al. Inf uence of inpatient service specialty on care processes and outcomes for patients with non ST-segment elevation acute coronary syndromes. Circulation 2007; 116: 1153-1161.
5. Fox KA, Anderson FA Jr, Dabbous OH, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart 2007; 93: 177-182.
6. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190-1201.
7. Nakamura M, Yamashita T, Yajima J, et al. Clinical outcome after acute coronary syndrome in Japanese patients: an observational cohort study. J Cardiol 2010; 55: 69-76.
8. Suzuki S, Sagara K, Otsuka T, et al. Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 2012; 76: 607-611.
9. Suzuki S, Yamashita T, Ohtsuka T, et al. Prevalence and prognosis of patients with atrial f brillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 2008; 72: 914-920.
10. Kaneko H, Yajima J, Oikawa Y, et al. Impact of aging on the clinical outcomes of Japanese patients with coronary artery disease after percutaneous coronary intervention. Heart Vessels 2013. (in press)
11. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
12. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332: 1426.
13. Kaneko H, Yajima J, Oikawa Y, et al. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels 2013. (in press)
14. Park MW, Seung KB, Kim PJ, et al. Long-term percutaneous coronary intervention rates and associated independent predictors for progression of nonintervened nonculprit coronary lesions. Am J Cardiol 2009; 104: 648-652.
15. Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005; 111: 143-149.
16. Kaneko H, Yajima J, Oikawa Y, et al. Role of arterial stiffness and impaired renal function in the progression of new coronary lesions after percutaneous coronary intervention. Cardiovasc Interv Ther 2013; 28: 56-62.
17. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.
18. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007; 297: 1985-1991.
19. Nishigaki K, Yamazaki T, Kitabatake A, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv 2008; 1: 469-479.
20. Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012; 125: 584-591.
21. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121: 2592-2600. (Review)
22. Laederach K, Weidmann P. Plasma and urinary catecholamines as related to renal function in man. Kidney Int 1987; 31: 107-111.
23. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
24. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angi-otensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
25. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neu-rohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-1609.
26. St. John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of cap-topril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997; 96: 3294-3299.
27. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. An-giotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
28. Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardi-ol 2003; 41: 2164-2171.
29. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxi-dative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insuff ciency. Kidney Int 2003; 63: 179-185.
30. Kinugawa S, Tsutsui H, Hayashidani S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000; 87: 392-398.
31. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002; 40: 834-839.
32. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bi-oavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.
33. Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982; 65: 281-285.
34. Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 2011; 305: 1882-1889.
35. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation 2004; 110: 1514-1517.
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
37. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
38. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
39. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
40. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
41. Dupuis J, Tardif JC, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3233.
42. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235.
43. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.